Omnicell, Inc. (OMCL) AI Stock Analysis

Omnicell, Inc. specializes in medication management solutions and adherence tools for pharmacies and healthcare systems across the United States and globally. Its offerings include point-of-care automation solutions like the XT Series automated dispensing systems for nursing units, clinical settings, and operating rooms. The company provides Omnicell Interface Software to connect medication-use products with facility information systems. Additionally, Omnicell delivers robotic dispensing systems, central pharmacy automation including the XR2 Automated Central Pharmacy System and IV compounding robots, alongside single-dose blister packaging solutions and automated filling equipment to improve medication adherence.

Omnicell generated $1.13B in revenue in FY2021 before peaking at $1.30B in FY2022. Revenue declined 11.5% in FY2023 to $1.15B and fell 3.0% in FY2024 to $1.11B, but rebounded 6.5% to $1.18B in FY2025. Gross margin compressed from 49.0% in FY2021 to 42.9% in FY2025, while operating margin fell from 7.9% to 1.0%. Net income moved from $77.8M in FY2021 to a loss of -$20.4M in FY2023, recovering to $2.1M in FY2025. For the trailing twelve months ended June 30, 2026, revenue stood at $1.25B with an operating margin of 5.9%, aided by second-quarter year-over-year revenue growth of 7.5% and earnings growth of 333.3%.

As of June 30, 2026, Omnicell held $307.0M in cash and short-term investments against $200.0M in total debt, resulting in a net cash position of $107.0M. The company maintains a current ratio of 1.64 and a debt-to-equity ratio of 0.15, supported by $1.29B in shareholders' equity. In FY2025, operating cash flow reached $127.3M and free cash flow was $86.9M. Capital allocation in FY2025 included $40.4M for capital expenditures and $77.6M directed toward share buybacks.

Omnicell trades at a trailing P/E of 42.1x and a forward P/E of 29.5x, compared to the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. Its price-to-sales multiple of 1.3x and EV/EBITDA of 9.8x sit below peer medians of 4.1x and 12.0x. Over the past year, OMCL returned 16.8%, matching the S&P 500 return of 16.8%. However, its five-year return of -77.6% substantially lagged the S&P 500 return of 83.0%, while the stock traded 10.7% below its 200-day moving average as of October 16, 2026.

Omnicell is covered by Wall Street analysts with 6 Strong Buy, 1 Buy, and 1 Hold ratings. The mean price target is $57.86, representing an upside of 63.5% above the last close of $35.39 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate EPS of $2.27 on revenue of $1.24B. Next fiscal year estimates project EPS of $2.06 and revenue of $1.29B. Omnicell has beaten EPS expectations in 3 of the last 4 quarters, with its next earnings scheduled for October 29, 2026.

This page is an AI-written research summary of Omnicell, Inc. (OMCL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OMCL income statement, OMCL balance sheet, OMCL key metrics, OMCL analyst forecast, OMCL chart. See the OMCL stock overview for the latest quote and news.